Nanotherapeutics for Antimicrobial Resistance: Pharmaceutical Approaches to a Global Crisis

Abstract

Antimicrobial resistance (AMR) has become a critical global health crisis, diminishing the effectiveness of conventional antibiotics and driving the need for innovative therapeutic strategies. Nanotechnology offers a powerful alternative by enabling improved drug delivery, enhanced stability, targeted release, and the ability to bypass common bacterial resistance mechanisms. Nanoparticles—including metal and metal-oxide systems, polymeric carriers, lipid-based structures, nanogels, carbon-based materials, and hybrid or stimuli-responsive platforms—demonstrate multifaceted antimicrobial activity through membrane disruption, biofilm penetration, controlled release, and synergistic drug combinations. These nanotherapeutic systems show efficacy against multidrug-resistant bacterial, viral, and fungal pathogens while reducing systemic toxicity and improving pharmacokinetics. Beyond treatment, nanotechnology enhances wound healing, supports antimicrobial device coatings, and advances precision targeting of infection sites. Despite significant promise, challenges persist in large-scale manufacturing, stability, toxicity assessment, and regulatory standardization. Continued advances in AI-guided nanoengineering, CRISPR-enabled antimicrobial systems, and bioinspired materials are expected to redefine the future of anti-infective therapy. Together, nanotherapeutics offer a transformative path forward in countering AMR and strengthening global infectious disease management.